Single-cell RNA-seq with spike-in cells enables accurate quantification of cell-specific drug effects in pancreatic islets.
Animals
Artemether
/ pharmacology
Cell Dedifferentiation
/ drug effects
Forkhead Transcription Factors
/ antagonists & inhibitors
Glucagon-Secreting Cells
/ drug effects
Humans
Insulin-Secreting Cells
/ drug effects
Islets of Langerhans
/ drug effects
Machine Learning
Mice
RNA-Seq
/ standards
Reference Standards
Single-Cell Analysis
/ standards
Species Specificity
Transcriptome
/ drug effects
Journal
Genome biology
ISSN: 1474-760X
Titre abrégé: Genome Biol
Pays: England
ID NLM: 100960660
Informations de publication
Date de publication:
06 05 2020
06 05 2020
Historique:
received:
19
07
2019
accepted:
27
03
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
24
2
2021
Statut:
epublish
Résumé
Single-cell RNA-seq (scRNA-seq) is emerging as a powerful tool to dissect cell-specific effects of drug treatment in complex tissues. This application requires high levels of precision, robustness, and quantitative accuracy-beyond those achievable with existing methods for mainly qualitative single-cell analysis. Here, we establish the use of standardized reference cells as spike-in controls for accurate and robust dissection of single-cell drug responses. We find that contamination by cell-free RNA can constitute up to 20% of reads in human primary tissue samples, and we show that the ensuing biases can be removed effectively using a novel bioinformatics algorithm. Applying our method to both human and mouse pancreatic islets treated ex vivo, we obtain an accurate and quantitative assessment of cell-specific drug effects on the transcriptome. We observe that FOXO inhibition induces dedifferentiation of both alpha and beta cells, while artemether treatment upregulates insulin and other beta cell marker genes in a subset of alpha cells. In beta cells, dedifferentiation and insulin repression upon artemether treatment occurs predominantly in mouse but not in human samples. This new method for quantitative, error-correcting, scRNA-seq data normalization using spike-in reference cells helps clarify complex cell-specific effects of pharmacological perturbations with single-cell resolution and high quantitative accuracy.
Sections du résumé
BACKGROUND
Single-cell RNA-seq (scRNA-seq) is emerging as a powerful tool to dissect cell-specific effects of drug treatment in complex tissues. This application requires high levels of precision, robustness, and quantitative accuracy-beyond those achievable with existing methods for mainly qualitative single-cell analysis. Here, we establish the use of standardized reference cells as spike-in controls for accurate and robust dissection of single-cell drug responses.
RESULTS
We find that contamination by cell-free RNA can constitute up to 20% of reads in human primary tissue samples, and we show that the ensuing biases can be removed effectively using a novel bioinformatics algorithm. Applying our method to both human and mouse pancreatic islets treated ex vivo, we obtain an accurate and quantitative assessment of cell-specific drug effects on the transcriptome. We observe that FOXO inhibition induces dedifferentiation of both alpha and beta cells, while artemether treatment upregulates insulin and other beta cell marker genes in a subset of alpha cells. In beta cells, dedifferentiation and insulin repression upon artemether treatment occurs predominantly in mouse but not in human samples.
CONCLUSIONS
This new method for quantitative, error-correcting, scRNA-seq data normalization using spike-in reference cells helps clarify complex cell-specific effects of pharmacological perturbations with single-cell resolution and high quantitative accuracy.
Identifiants
pubmed: 32375897
doi: 10.1186/s13059-020-02006-2
pii: 10.1186/s13059-020-02006-2
pmc: PMC7201533
doi:
Substances chimiques
Forkhead Transcription Factors
0
Artemether
C7D6T3H22J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
106Subventions
Organisme : NIDDK NIH HHS
ID : U24 DK098085
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK098085
Pays : United States
Références
Genome Res. 2005 Oct;15(10):1388-92
pubmed: 16204192
Cell Death Discov. 2018 Feb 9;4:14
pubmed: 29531811
Mol Metab. 2016 Jan 11;5(3):233-244
pubmed: 26977395
BMC Genomics. 2017 Jul 7;18(1):519
pubmed: 28687070
J Clin Invest. 2017 Jan 3;127(1):244-259
pubmed: 27941248
Biomed Res Int. 2018 May 13;2018:8639523
pubmed: 29862294
Diabetologia. 2017 Jun;60(6):1033-1042
pubmed: 28280900
Cell Metab. 2017 Mar 7;25(3):622-634
pubmed: 28215845
Diabetes. 2013 Jul;62(7):2595-604
pubmed: 23524641
Elife. 2017 Dec 05;6:
pubmed: 29206104
FASEB J. 2019 Jul;33(7):8241-8248
pubmed: 30916998
J Biol Chem. 2016 May 6;291(19):10162-72
pubmed: 26984405
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6646-51
pubmed: 9192619
Nat Commun. 2016 Aug 30;7:12631
pubmed: 27572106
Nature. 2010 Apr 22;464(7292):1149-54
pubmed: 20364121
FASEB J. 2019 Mar;33(3):3968-3984
pubmed: 30509117
Diabetes. 2013 Nov;62(11):3760-5
pubmed: 23995958
Cell Syst. 2016 Oct 26;3(4):346-360.e4
pubmed: 27667365
Cell Metab. 2016 Oct 11;24(4):608-615
pubmed: 27667665
Nat Commun. 2018 Jul 10;9(1):2667
pubmed: 29991676
Nat Rev Genet. 2017 Aug;18(8):473-484
pubmed: 28626224
Cell Metab. 2018 Nov 6;28(5):787-792.e3
pubmed: 30057067
Diabetologia. 2010 Jan;53(1):128-38
pubmed: 19851748
Int J Obes (Lond). 2010 Nov;34(11):1599-607
pubmed: 20498660
Life Sci. 2019 Feb 15;219:353-363
pubmed: 30684545
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11692-7
pubmed: 21709230
Diabetes. 2016 Oct;65(10):3028-38
pubmed: 27364731
Cell Metab. 2017 May 2;25(5):1160-1175.e11
pubmed: 28467932
Diabetes. 2015 Sep;64(9):3172-81
pubmed: 25931473
Cell. 2017 Jan 12;168(1-2):86-100.e15
pubmed: 27916275
Nature. 2019 Mar;567(7746):43-48
pubmed: 30760930
Nature. 2014 Oct 23;514(7523):503-7
pubmed: 25141178
Diabetes. 2018 Sep;67(9):1783-1794
pubmed: 29950394
EMBO Rep. 2016 Feb;17(2):178-87
pubmed: 26691212
Genes Dev. 2011 Aug 15;25(16):1680-5
pubmed: 21852533
Cell Rep. 2019 Nov 5;29(6):1718-1727.e8
pubmed: 31693907
Endocrinology. 2016 Sep;157(9):3431-8
pubmed: 27466694
Cell. 2012 Sep 14;150(6):1223-34
pubmed: 22980982
Cell Syst. 2019 Apr 24;8(4):281-291.e9
pubmed: 30954476
Mol Pharmacol. 2010 Nov;78(5):961-70
pubmed: 20736318
Front Pharmacol. 2019 Apr 26;10:445
pubmed: 31133849
J Diabetes Res. 2019 Feb 26;2019:5783545
pubmed: 30937314
Front Pharmacol. 2015 Nov 10;6:260
pubmed: 26617516
Am J Transl Res. 2019 Mar 15;11(3):1389-1402
pubmed: 30972169
Diabetes. 2014 Sep;63(9):3128-34
pubmed: 25146474
PLoS Genet. 2013 Oct;9(10):e1003934
pubmed: 24204325
Cell Syst. 2016 Oct 26;3(4):385-394.e3
pubmed: 27693023
Diabetes. 2014 Dec;63(12):4197-205
pubmed: 25008178
Cell. 2018 Feb 22;172(5):1091-1107.e17
pubmed: 29474909
Cell. 2009 Aug 7;138(3):449-62
pubmed: 19665969
J Diabetes. 2019 Jul;11(7):563-572
pubmed: 30520247
Cell. 2017 Oct 5;171(2):321-330.e14
pubmed: 28965763
Dev Cell. 2011 Apr 19;20(4):419-29
pubmed: 21497756
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
Cell Res. 2016 Oct;26(10):1169-1172
pubmed: 27633061
Nature. 2018 Oct;562(7727):367-372
pubmed: 30283141
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3293-8
pubmed: 26951663
J Clin Invest. 2013 Mar;123(3):1275-84
pubmed: 23434589
Sci Rep. 2017 Jul 10;7(1):5024
pubmed: 28694456
Cell Metab. 2018 Jan 9;27(1):218-225.e4
pubmed: 29103923
Sci Rep. 2017 Mar 23;7(1):374
pubmed: 28336918
Cell Metab. 2017 May 2;25(5):1194-1205.e4
pubmed: 28467935
Cell Metab. 2016 Oct 11;24(4):593-607
pubmed: 27667667